Atlas company financials

AbbVie Inc.

Standardized 15-year financial series for AbbVie Inc., built from filing-derived source data and exposed in JSON, CSV, and XLSX so it can feed iterFact artifacts or analyst workflows without hand-entering the numbers.

United StatesCIK 0001551152FY2011 → FY2025

Open JSON Download CSV Download XLSX Quarterly JSON Summary JSON Filing index

Latest fiscal year

FY2025

Revenue

$61.2B

Adjusted EBITDA

—

Net result

$4.2B

Net financial debt

$61.8B

Latest source: FY2025 filing · published data snapshot generated April 26, 2026

Phase 2 summary

Latest quarter, TTM, and growth are now pre-computed for chat and templates.

Latest quarter revenue

$15.8B

TTM revenue

$59B

TTM free cash flow

—

Latest quarter net result

$186M

Quarterly coverage: 42 periods · latest quarter FY2025-Q3 · TTM revenue growth 8.1%.

What this gives you

A proof-of-concept company data surface, not a dead PDF shelf.

The same standardized payload behind this page is exposed through downloadable CSV and XLSX files plus a stable JSON route. That makes it usable as a live input to iterFact templates, a spreadsheet handoff, or a future API surface without re-normalizing the source documents again.

Source audit

Official links first, raw iterFact payloads right next to them.

Official sources

SEC EDGAR companyfacts
comparative · abbvie-inc-fy2011 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2014-02-21 · Retrieved: 2026-04-26T11:38:09.653359+00:00
SEC EDGAR companyfacts
primary · abbvie-inc-fy2014 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2015-02-20 · Retrieved: 2026-04-26T11:38:09.653359+00:00
SEC EDGAR companyfacts
us-gaap:NetIncomeLoss · us gaap companyfacts · comparative · abbvie-inc-fy2014 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2017-02-17 · Retrieved: 2026-04-26T11:38:09.653359+00:00
SEC EDGAR companyfacts
primary · abbvie-inc-fy2015 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2016-02-19 · Retrieved: 2026-04-26T11:38:09.653359+00:00
SEC EDGAR companyfacts
primary · abbvie-inc-fy2017 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2018-02-16 · Retrieved: 2026-04-26T11:38:09.653359+00:00

Ten-year series

Headline company financials by fiscal year

Fiscal year	Revenue	Adj. EBITDA	EBIT	Net result	Op. cash flow	Capex	Net debt	Status
FY2011	17B	—	4B	—	6B	-356M	—	comparative annual fact carried from later 10k · missing accounts receivable · missing adjusted ebitda · missing current assets · missing current liabilities · missing gross profit · missing interest expense · missing inventory · missing net financial debt · missing net result · missing research and development · missing total assets · missing total equity
FY2012	18B	—	6B	—	6B	-333M	-5B	comparative annual fact carried from later 10k · missing accounts receivable · missing adjusted ebitda · missing gross profit · missing net result · missing research and development
FY2013	19B	—	6B	—	6B	-491M	-9B	missing accounts receivable · missing adjusted ebitda · missing gross profit · missing net result · missing research and development
FY2014	20B	—	3B	2B	4B	-612M	-8B	missing accounts receivable · missing adjusted ebitda · missing gross profit · missing research and development
FY2015	23B	—	8B	5B	8B	-532M	-8B	missing accounts receivable · missing adjusted ebitda · missing gross profit · missing research and development
FY2016	26B	—	9B	6B	7B	-479M	-5B	missing accounts receivable · missing adjusted ebitda · missing gross profit · missing research and development
FY2017	28B	—	10B	5B	10B	-529M	-9B	missing adjusted ebitda · missing gross profit · missing research and development
FY2018	33B	—	6B	6B	13B	-638M	-4B	missing adjusted ebitda · missing gross profit · missing research and development

Filing provenance